Seoulin Bioscience Co.,Ltd.

As of March 31, 2026, Seoulin Bioscience Co.,Ltd. carries a market capitalization of 53.53B, placing it among publicly traded companies globally. Its enterprise value stands at 32.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Seoulin Bioscience Co.,Ltd. has 8.82M shares outstanding.

As of March 31, 2026, Seoulin Bioscience Co.,Ltd. trades at a trailing price-to-earnings ratio of 102.82. The price-to-sales ratio is 0.68, and the price-to-book ratio stands at 0.64.

As of March 31, 2026, Seoulin Bioscience Co.,Ltd. trades at an EV/EBITDA multiple of 16.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 42.15 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Seoulin Bioscience Co.,Ltd. trades at an EV/FCF ratio of 21.38, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 32.42B versus a market cap of 53.53B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Seoulin Bioscience Co.,Ltd. maintains a current ratio of 2.23, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.93, indicating elevated leverage, while an interest coverage ratio of 1.97 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Seoulin Bioscience Co.,Ltd. posted a return on equity (ROE) of 0.62, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.56 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 0.47, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.36, useful for judging operating efficiency across full business cycles. The company generates approximately 714.41M in revenue per employee across its workforce of 110.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.52 indicates how many times Seoulin Bioscience Co.,Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Seoulin Bioscience Co.,Ltd. recorded 217.36M in income tax expense. That works out to an effective tax rate of 33.34, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 651.99M, leaving 518.17M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Seoulin Bioscience Co.,Ltd.'s stock has declined approximately 42.68% over the past 52 weeks. The 50-day moving average sits at 4,146.20, while the 200-day moving average is 5,360.34.

Over the twelve months ended March 31, 2026, Seoulin Bioscience Co.,Ltd. generated 78.58B in revenue and converted that into 518.17M in net income, yielding earnings per share of 46.05. EBITDA reached 1.92B, while operating income came in at 769.10M.

As of March 31, 2026, Seoulin Bioscience Co.,Ltd. holds 34.82B in cash and equivalents against 11.88B in total debt, resulting in a net debt position of 907.35M. Total book value stands at 83.51B, with working capital of 40.38B providing operational flexibility.

Seoulin Bioscience Co.,Ltd. produced 1.36B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -489.09M in capital expenditures, free cash flow totaled 868.55M - equivalent to 98.95 per share.

Over the twelve months ended March 31, 2026, Seoulin Bioscience Co.,Ltd. posted a gross margin of 21.95, reflecting its pricing power and cost economics. The operating margin of 0.98 and net profit margin of 0.66 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Seoulin Bioscience Co.,Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.52, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -31.17, meaning Seoulin Bioscience Co.,Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Seoulin Bioscience Co.,Ltd.'s most recent stock split took place on December 29, 2025 with a 647:662 split ratio.

As of March 31, 2026, Seoulin Bioscience Co.,Ltd. has an Altman Z-Score of 2.83, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.